FDA
-
-
-
-
-
-
-
William Blair Reiterates Outperform Rating on Harrow Health (HROW): "We believe the long-term growth outlook is attractive"
-
-
-
-
-
-
-
Harrow Announces Closing of Acquisition of Melt Pharmaceuticals
-
-
-
-
-
-
-
Harrow Announces Second-Quarter 2025 Financial Results
-
-
-
-
-
-
-
Harrow Announces First-Quarter 2025 Financial Results
-
-
-
-
-
-
-
Harrow Health (HROW) Appoints Amir H. Shojaei as Chief Scientific Officer
-
-
-
-
-
-
-
Harrow Relaunches TRIESENCE®
-
-
-
-
-
-
-
Harrow Announces 52-Week Data from VEVYE® ESSENCE-2 Open-Label Extension Study
-
323,582 total articles have been posted to this entity.
Click Here to Sign-Up for StreetInsider.com Premium to View All

